O	0	10	Expression	Expression	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	17	Bcl	Bcl	NN	B-NP
O	17	18	-	-	HYPH	O
O	18	20	xL	xL	NN	B-NP
O	20	21	,	,	,	O
O	22	25	Bax	Bax	NN	B-NP
O	25	26	,	,	,	O
O	27	30	and	and	CC	O
O	31	34	p53	p53	NN	B-NP
O	35	37	in	in	IN	B-PP
B-Cancer	38	45	primary	primary	JJ	B-NP
I-Cancer	46	52	tumors	tumor	NNS	I-NP
O	53	56	and	and	CC	O
B-Cancer	57	62	lymph	lymph	NN	B-NP
I-Cancer	63	67	node	node	NN	I-NP
I-Cancer	68	78	metastases	metastasis	NNS	I-NP
O	79	81	in	in	IN	B-PP
B-Cancer	82	86	oral	oral	JJ	B-NP
I-Cancer	87	95	squamous	squamous	JJ	I-NP
I-Cancer	96	100	cell	cell	NN	I-NP
I-Cancer	101	110	carcinoma	carcinoma	NN	I-NP
O	110	111	.	.	.	O

O	113	125	Disturbances	Disturbance	NNS	B-NP
O	126	128	in	in	IN	B-PP
O	129	139	expression	expression	NN	B-NP
O	140	142	of	of	IN	B-PP
O	143	152	apoptosis	apoptosis	NN	B-NP
O	152	153	-	-	HYPH	B-NP
O	153	163	associated	associate	VBN	I-NP
O	164	172	proteins	protein	NNS	I-NP
O	173	177	take	take	VBP	B-VP
O	178	182	part	part	NN	B-NP
O	183	185	in	in	IN	B-PP
O	186	189	the	the	DT	B-NP
O	190	201	development	development	NN	I-NP
O	202	205	and	and	CC	I-NP
O	206	217	progression	progression	NN	I-NP
O	218	220	of	of	IN	B-PP
O	221	225	many	many	JJ	B-NP
O	226	231	human	human	JJ	I-NP
B-Cancer	232	244	malignancies	malignancy	NNS	I-NP
O	244	245	.	.	.	O

O	246	249	The	The	DT	B-NP
O	250	253	aim	aim	NN	I-NP
O	254	256	of	of	IN	B-PP
O	257	261	this	this	DT	B-NP
O	262	267	study	study	NN	I-NP
O	268	271	was	be	VBD	B-VP
O	272	275	the	the	DT	B-NP
O	276	286	assessment	assessment	NN	I-NP
O	287	289	of	of	IN	B-PP
O	290	302	correlations	correlation	NNS	B-NP
O	303	308	among	among	IN	B-PP
O	309	317	proteins	protein	NNS	B-NP
O	318	326	involved	involve	VBN	B-VP
O	327	329	in	in	IN	B-PP
O	330	339	apoptosis	apoptosis	NN	B-NP
O	339	340	-	-	HYPH	B-NP
O	340	343	Bcl	Bcl	NN	I-NP
O	343	344	-	-	HYPH	O
O	344	346	xL	xL	NN	B-NP
O	346	347	,	,	,	O
O	348	351	Bax	Bax	NN	B-NP
O	351	352	,	,	,	O
O	353	356	and	and	CC	O
O	357	360	p53	p53	NN	B-NP
O	360	361	-	-	HYPH	O
O	361	363	as	as	RB	B-CONJP
O	364	368	well	well	RB	I-CONJP
O	369	371	as	as	IN	I-CONJP
O	372	385	relationships	relationship	NNS	B-NP
O	386	388	of	of	IN	B-PP
O	389	394	these	these	DT	B-NP
O	395	403	proteins	protein	NNS	I-NP
O	404	408	with	with	IN	B-PP
O	409	417	selected	select	VBN	B-NP
O	418	437	clinicopathological	clinicopathological	JJ	I-NP
O	438	446	features	feature	NNS	I-NP
O	447	449	in	in	IN	B-PP
B-Cancer	450	454	oral	oral	JJ	B-NP
I-Cancer	455	463	squamous	squamous	JJ	I-NP
I-Cancer	464	468	cell	cell	NN	I-NP
I-Cancer	469	478	carcinoma	carcinoma	NN	I-NP
O	478	479	.	.	.	O

O	480	492	Consequently	Consequently	RB	B-ADVP
O	492	493	,	,	,	O
O	494	496	we	we	PRP	B-NP
O	497	505	examined	examine	VBD	B-VP
O	506	508	by	by	IN	B-PP
O	509	529	immunohistochemistry	immunohistochemistry	NN	B-NP
O	529	530	,	,	,	O
O	531	536	using	use	VBG	B-VP
O	537	540	the	the	DT	B-NP
O	541	547	avidin	avidin	NN	I-NP
O	547	548	-	-	HYPH	B-NP
O	548	554	biotin	biotin	NN	I-NP
O	554	555	-	-	HYPH	I-NP
O	555	565	peroxidase	peroxidase	NN	I-NP
O	566	572	method	method	NN	I-NP
O	572	573	,	,	,	O
O	574	577	Bcl	Bcl	NN	B-NP
O	577	578	-	-	HYPH	O
O	578	580	xL	xL	NN	B-NP
O	580	581	,	,	,	O
O	582	585	Bax	Bax	NN	B-NP
O	585	586	,	,	,	O
O	587	590	and	and	CC	O
O	591	594	p53	p53	NN	B-NP
O	595	605	expression	expression	NN	I-NP
O	606	608	in	in	IN	B-PP
O	609	611	56	56	CD	B-NP
B-Cancer	612	619	samples	sample	NNS	I-NP
O	620	622	of	of	IN	B-PP
B-Cancer	623	630	primary	primary	JJ	B-NP
I-Cancer	631	635	oral	oral	JJ	I-NP
I-Cancer	636	644	squamous	squamous	JJ	I-NP
I-Cancer	645	649	cell	cell	NN	I-NP
I-Cancer	650	659	carcinoma	carcinoma	NN	I-NP
O	660	663	and	and	CC	O
O	664	666	in	in	IN	B-PP
O	667	669	22	22	CD	B-NP
O	670	677	matched	match	VBN	I-NP
O	678	683	pairs	pair	NNS	I-NP
O	684	686	of	of	IN	B-PP
B-Cancer	687	694	primary	primary	JJ	B-NP
O	695	698	and	and	CC	I-NP
B-Cancer	699	709	metastatic	metastatic	JJ	I-NP
I-Cancer	710	716	tumors	tumor	NNS	I-NP
O	716	717	.	.	.	O

O	718	721	The	The	DT	B-NP
O	722	732	evaluation	evaluation	NN	I-NP
O	733	735	of	of	IN	B-PP
O	736	750	immunostaining	immunostaining	NN	B-NP
O	751	753	of	of	IN	B-PP
O	754	757	Bcl	Bcl	NN	B-NP
O	757	758	-	-	HYPH	O
O	758	760	xL	xL	NN	B-NP
O	760	761	,	,	,	O
O	762	765	Bax	Bax	NN	B-NP
O	765	766	,	,	,	O
O	767	770	and	and	CC	O
O	771	774	p53	p53	NN	B-NP
O	775	778	was	be	VBD	B-VP
O	779	787	analyzed	analyze	VBN	I-VP
O	788	790	in	in	IN	B-PP
O	791	793	10	10	CD	B-NP
O	794	803	different	different	JJ	I-NP
B-Cancer	804	809	tumor	tumor	NN	I-NP
O	810	816	fields	field	NNS	I-NP
O	816	817	,	,	,	O
O	818	821	and	and	CC	O
O	822	825	the	the	DT	B-NP
O	826	830	mean	mean	JJ	I-NP
O	831	841	percentage	percentage	NN	I-NP
O	842	844	of	of	IN	B-PP
B-Cell	845	850	tumor	tumor	NN	B-NP
I-Cell	851	856	cells	cell	NNS	I-NP
O	857	861	with	with	IN	B-PP
O	862	870	positive	positive	JJ	B-NP
O	871	879	staining	staining	NN	I-NP
O	880	883	was	be	VBD	B-VP
O	884	893	evaluated	evaluate	VBN	I-VP
O	893	894	.	.	.	O

O	895	898	The	The	DT	B-NP
O	899	911	significance	significance	NN	I-NP
O	912	914	of	of	IN	B-PP
O	915	918	the	the	DT	B-NP
O	919	931	associations	association	NNS	I-NP
O	932	935	was	be	VBD	B-VP
O	936	946	determined	determine	VBN	I-VP
O	947	952	using	use	VBG	B-VP
O	953	961	Spearman	Spearman	NNP	B-NP
O	962	973	correlation	correlation	NN	I-NP
O	974	982	analysis	analysis	NN	I-NP
O	983	986	and	and	CC	O
O	987	990	the	the	DT	B-NP
O	991	994	chi	chi	AFX	I-NP
O	994	995	-	-	HYPH	I-NP
O	995	1001	square	square	JJ	I-NP
O	1002	1006	test	test	NN	I-NP
O	1006	1007	.	.	.	O

O	1008	1010	We	We	PRP	B-NP
O	1011	1016	found	find	VBD	B-VP
O	1017	1025	positive	positive	JJ	B-NP
O	1026	1029	Bcl	Bcl	NN	I-NP
O	1029	1030	-	-	HYPH	O
O	1030	1032	xL	xL	NN	B-NP
O	1032	1033	,	,	,	O
O	1034	1037	Bax	Bax	NN	B-NP
O	1037	1038	,	,	,	O
O	1039	1042	and	and	CC	O
O	1043	1046	p53	p53	NN	B-NP
O	1047	1061	immunostaining	immunostaining	NN	I-NP
O	1062	1064	in	in	IN	B-PP
O	1065	1067	44	44	CD	B-NP
O	1067	1068	.	.	.	O
O	1068	1069	6	6	CD	B-NP
O	1069	1070	%	%	NN	I-NP
O	1070	1071	,	,	,	O
O	1072	1074	28	28	CD	B-NP
O	1074	1075	.	.	.	O
O	1075	1076	6	6	CD	B-NP
O	1076	1077	%	%	NN	I-NP
O	1077	1078	,	,	,	O
O	1079	1082	and	and	CC	O
O	1083	1085	58	58	CD	B-NP
O	1085	1086	.	.	.	O
O	1086	1087	9	9	CD	B-NP
O	1087	1088	%	%	NN	I-NP
O	1089	1091	of	of	IN	B-PP
O	1092	1095	the	the	DT	B-NP
O	1096	1103	studied	study	VBN	I-NP
B-Cancer	1104	1111	primary	primary	JJ	I-NP
I-Cancer	1112	1118	tumors	tumor	NNS	I-NP
O	1119	1122	and	and	CC	O
O	1123	1125	in	in	IN	B-PP
O	1126	1128	63	63	CD	B-NP
O	1128	1129	.	.	.	O
O	1129	1130	6	6	CD	B-NP
O	1130	1131	%	%	NN	I-NP
O	1131	1132	,	,	,	O
O	1133	1135	45	45	CD	B-NP
O	1135	1136	.	.	.	O
O	1136	1137	5	5	CD	B-NP
O	1137	1138	%	%	NN	I-NP
O	1138	1139	,	,	,	O
O	1140	1143	and	and	CC	O
O	1144	1146	72	72	CD	B-NP
O	1146	1147	.	.	.	O
O	1147	1148	7	7	CD	B-NP
O	1148	1149	%	%	NN	I-NP
O	1150	1152	of	of	IN	B-PP
B-Cancer	1153	1158	lymph	lymph	NN	B-NP
I-Cancer	1159	1163	node	node	NN	I-NP
I-Cancer	1164	1174	metastases	metastasis	NNS	I-NP
O	1174	1175	,	,	,	O
O	1176	1188	respectively	respectively	RB	B-ADVP
O	1188	1189	.	.	.	O

O	1190	1198	Analysis	Analysis	NN	B-NP
O	1199	1201	of	of	IN	B-PP
O	1202	1214	associations	association	NNS	B-NP
O	1215	1220	among	among	IN	B-PP
O	1221	1228	studied	study	VBN	B-NP
O	1229	1237	proteins	protein	NNS	I-NP
O	1238	1246	revealed	reveal	VBD	B-VP
O	1247	1255	positive	positive	JJ	B-NP
O	1256	1267	correlation	correlation	NN	I-NP
O	1268	1275	between	between	IN	B-PP
O	1276	1279	Bcl	Bcl	NN	B-NP
O	1279	1280	-	-	HYPH	I-NP
O	1280	1282	xL	xL	NN	I-NP
O	1283	1286	and	and	CC	I-NP
O	1287	1290	Bax	Bax	NN	I-NP
O	1291	1293	in	in	IN	B-PP
B-Cancer	1294	1301	primary	primary	JJ	B-NP
I-Cancer	1302	1308	tumors	tumor	NNS	I-NP
O	1309	1310	(	(	(	O
O	1310	1311	P	P	NN	B-NP
O	1311	1312	<	<	SYM	B-ADJP
O	1312	1313	0	0	CD	B-NP
O	1313	1314	.	.	.	I-NP
O	1314	1316	03	03	CD	I-NP
O	1316	1317	,	,	,	O
O	1318	1319	r	r	NN	B-NP
O	1319	1320	=	=	SYM	B-VP
O	1320	1321	0	0	CD	B-NP
O	1321	1322	.	.	SYM	I-NP
O	1322	1325	307	307	CD	I-NP
O	1325	1326	)	)	)	O
O	1326	1327	.	.	.	O

O	1328	1341	Statistically	Statistically	RB	B-NP
O	1342	1353	significant	significant	JJ	I-NP
O	1354	1366	relationship	relationship	NN	I-NP
O	1367	1374	between	between	IN	B-PP
O	1375	1378	p53	p53	NN	B-NP
O	1379	1389	expression	expression	NN	I-NP
O	1390	1392	in	in	IN	B-PP
B-Cancer	1393	1400	primary	primary	JJ	B-NP
I-Cancer	1401	1405	oral	oral	JJ	I-NP
I-Cancer	1406	1413	cancers	cancer	NNS	I-NP
O	1414	1417	and	and	CC	O
O	1418	1421	its	its	PRP$	B-NP
O	1422	1432	expression	expression	NN	I-NP
O	1433	1435	in	in	IN	B-PP
B-Cancer	1436	1441	lymph	lymph	NN	B-NP
I-Cancer	1442	1446	node	node	NN	I-NP
I-Cancer	1447	1457	metastases	metastasis	NNS	I-NP
O	1458	1459	(	(	(	O
O	1459	1460	P	P	NN	B-NP
O	1460	1461	<	<	SYM	B-ADJP
O	1461	1462	0	0	CD	B-NP
O	1462	1463	.	.	.	I-NP
O	1463	1465	02	02	CD	I-NP
O	1465	1466	)	)	)	O
O	1467	1469	as	as	RB	B-CONJP
O	1470	1474	well	well	RB	I-CONJP
O	1475	1477	as	as	IN	I-CONJP
O	1478	1487	increased	increase	VBN	B-NP
O	1488	1498	expression	expression	NN	I-NP
O	1499	1501	of	of	IN	B-PP
O	1502	1505	Bcl	Bcl	NN	B-NP
O	1505	1506	-	-	HYPH	B-NP
O	1506	1508	xL	xL	NN	I-NP
O	1508	1509	,	,	,	O
O	1510	1513	Bax	Bax	NN	B-NP
O	1513	1514	,	,	,	O
O	1515	1518	and	and	CC	O
O	1519	1522	p53	p53	NN	B-NP
O	1523	1525	in	in	IN	B-PP
B-Cancer	1526	1536	metastatic	metastatic	JJ	B-NP
I-Cancer	1537	1542	sites	site	NNS	I-NP
O	1543	1551	compared	compare	VBN	B-PP
O	1552	1556	with	with	IN	B-PP
B-Cancer	1557	1564	primary	primary	JJ	B-NP
I-Cancer	1565	1571	tumors	tumor	NNS	I-NP
O	1572	1577	could	could	MD	B-VP
O	1578	1586	indicate	indicate	VB	I-VP
O	1587	1589	an	an	DT	B-NP
O	1590	1601	association	association	NN	I-NP
O	1602	1604	of	of	IN	B-PP
O	1605	1610	these	these	DT	B-NP
O	1611	1619	proteins	protein	NNS	I-NP
O	1620	1624	with	with	IN	B-PP
B-Cancer	1625	1629	oral	oral	JJ	B-NP
I-Cancer	1630	1636	cancer	cancer	NN	I-NP
O	1637	1648	progression	progression	NN	I-NP
O	1649	1652	and	and	CC	I-NP
O	1653	1664	development	development	NN	I-NP
O	1665	1667	of	of	IN	B-PP
B-Cancer	1668	1678	metastases	metastasis	NNS	B-NP
O	1678	1679	.	.	.	O

O	1680	1688	Moreover	Moreover	RB	B-ADVP
O	1688	1689	,	,	,	O
O	1690	1692	we	we	PRP	B-NP
O	1693	1700	suppose	suppose	VBP	B-VP
O	1701	1705	that	that	IN	B-SBAR
O	1706	1715	knowledge	knowledge	NN	B-NP
O	1716	1721	about	about	IN	B-PP
O	1722	1735	heterogeneity	heterogeneity	NN	B-NP
O	1736	1743	between	between	IN	B-PP
B-Cancer	1744	1751	primary	primary	JJ	B-NP
O	1752	1755	and	and	CC	I-NP
B-Cancer	1756	1766	metastatic	metastatic	JJ	I-NP
I-Cancer	1767	1772	tumor	tumor	NN	I-NP
O	1773	1778	might	might	MD	B-VP
O	1779	1783	help	help	VB	I-VP
O	1784	1786	to	to	TO	I-VP
O	1787	1797	understand	understand	VB	I-VP
O	1798	1808	mechanisms	mechanism	NNS	B-NP
O	1809	1811	of	of	IN	B-PP
B-Cancer	1812	1816	oral	oral	JJ	B-NP
I-Cancer	1817	1823	cancer	cancer	NN	I-NP
O	1824	1835	progression	progression	NN	I-NP
O	1835	1836	.	.	.	O

